Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 82009-057

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 82009-057). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Venlafaxine Fig1)

A forest plot chart showing the fold change and 90% confidence intervals of pharmacokinetic parameters (Cmax and AUC) for venlafaxine and its metabolite ODV across various special populations, including hepatic impairment, renal impairment, CYP2D6 polymorphism, age over 60 years, and gender differences. The x-axis represents the change relative to the reference value.*

FDA Label Image

Figure (Venlafaxine Fig2)

A scatter plot chart showing the fold change and 90% confidence intervals of venlafaxine pharmacokinetics when co-administered with various interacting drugs. The x-axis represents the change relative to the reference value, while the y-axis lists several interacting drugs and analyte measurements including Cmax and AUC. Data points illustrate the effect of these drugs on venlafaxine's pharmacokinetic parameters.*

FDA Label Image

Figure (Venlafaxine Fig3)

A chart depicting pharmacokinetic fold changes and 90% confidence intervals for various interacting drugs and analytes relative to a reference value. The chart lists drugs such as ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium, displaying their Cmax and AUC changes as dots with horizontal confidence interval bars on a scale ranging approximately from 0 to 3 fold change.*

FDA Label Image

Package Label-principal Display Panel (37.5 mg (15 Capsule Bottle))

Label for Venlafaxine Hydrochloride Extended-Release Capsules USP 37.5 mg by Quallent Pharmaceuticals Health LLC. The label indicates a quantity of 1,000 capsules, manufactured by Aurobindo Pharma Limited, Hyderabad, India. It includes storage instructions, a barcode, and directions for pharmacists to dispense the Medication Guide separately. The label also displays the NDC 82009-056-10.*

FDA Label Image

Package Label-principal Display Panel (75 mg (15 Capsule Bottle))

Label for Venlafaxine Hydrochloride Extended-Release Capsules USP 75 mg by Quallent Pharmaceuticals Health LLC. The label indicates a pack size of 1,000 capsules, manufactured by Aurobindo Pharma Limited in India. It contains storage instructions, a pharmacist note to dispense medication guides, and dosage form as extended-release capsules.*

FDA Label Image

Package Label-principal Display Panel (150 mg (15 Capsule Bottle))

Label for Venlafaxine Hydrochloride Extended-Release Capsules USP 150 mg, in a bottle containing 500 capsules. The label includes the NDC 82009-058-05, manufacturer Aurobindo Pharma Limited, and labeler Quallent Pharmaceuticals Health LLC. Storage instructions (20° to 25°C) and dispensing information are provided, along with a barcode and branding for Quallent Pharmaceuticals.*

FDA Label Image

Chemical Structure (Venlafaxine Str)

Chemical structure of venlafaxine hydrochloride, showing the molecular arrangement including a cyclohexane ring, methoxyphenyl group, and dimethylaminoethyl side chain with the hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.